1. Corthay A (2014) Does the immune system naturally protect against cancer? Front Immunol 5:197. doi:10.3389/fimmu.2014.00197

2. Burnet M (1957) Cancer: a biological approach III viruses associated with neoplastic conditions IV practical applications. Br Med J 1:841–847. doi:10.1136/bmj.1.5023.841

3. Thomas L (1959) Discussion in: Lawrence HS (ed) Cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York, pp 529–532

4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumour escape. Nat Immunol 3:991–998. doi:10.1038/ni1102-991

5. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosureveillance and immunoediting. Immunity 21:137–148. doi:10.1016/j.immuni.2004.07.017

6. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360. doi:10.1146/annurev.immunol.22.012703.104803

7. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. doi:10.1126/science.1203486

8. Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumour microenvironment. Cancer Cell 21:309–322. doi:10.1016/j.ccr.2012.02.022

9. Barcellos-Hoff MH, Lyden D, Wang TC (2013) The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 13:511–518. doi:10.1038/nrc3536

10. Yaguchi T, Kawakami Y (2016) Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol 28:393–399. doi:10.1093/intimm/dxw030

11. Rödel F, Frey B, Gaipl U, Keilholz L, Fournier C, Manda K et al (2012) Modulation of inflammatory immune reactions by low-dose ionizing radiation: Molecular mechanisms and clinical applications. Curr Medic Chem 19:1741–1750. doi:10.2174/092986712800099866

12. Burnette B, Fu YX, Weichselbaum RR (2012) The confluence of radiotherapy and immunotherapy. Front Oncol 2:143. doi:10.3389/fonc.2012.00143

13. Kaur P, Asea A (2012) Radiation-induced effects and the immune system in cancer. Front Oncol. doi:10.3389/fonc.2012.00191

14. Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105:256–265. doi:10.1093/jnci/djs629

15. Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC (2014) The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 182:170–181. doi:10.1667/RR13500.1

16. Draghiciu O, Walczak M, Hoogeboom BN, Franken KL, Melief KJ, Nijman HW, Daemen T (2014) Therapeutic immunization and local low-dose tumour irradiation, a reinforcing combination. Int J Cancer 134:859–872. doi:10.1002/ijc.28418

17. Frey B, Rubner Y, Kulzer L, Werthmöller N, Weiss EM, Fietkau R, Gaipl US (2014) Antitumour immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63:29–36. doi:10.1007/s00262-013-1474-y

18. Wattenberg MM, Fahim A, Ahmed MM, Hodge JW (2014) Unlocking the combination: potentiation of radiation-induced antitumour responses with immunotherapy. Radiat Res 182:126–138. doi:10.1667/RR13374.1

19. Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25:11–17. doi:10.1016/j.semradonc.2014.07.005

20. Kumari A, Simon SS, Moody TD, Garnett-Benson C (2016) Immunomodulatory effects of radiation; what is next for cancer therapy? Future Oncol 12:239–256. doi:10.2217/fon.15.300

21. Tubiana M (2009) Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 91:4–15. doi:10.1016/j.radonc.2008.12.016

22. Gudowska I, Ardenfors O, Toma-Dasu I, Dasu A (2014) Radiation burden from secondary doses to patients undergoing radiation therapy with photons and light ions and radiation doses from imaging modalities. Radiat Prot Dosim 161:357–362. doi:10.1093/rpd/nct335

23. Ng J, Shuryak I (2015) Minimizing second cancer risk following radiotherapy: current perspectives. Cancer Manag Res 7:1–11. doi:10.2147/CMAR.S47220

24. Albrecht H, Durbin-Johnson B, Yunis R, Kalanetra KM, Wu S, Chen R et al (2012) Transcriptional response of ex vivo human skin to ionizing radiation: comparison between low- and high-dose effects. Radiat Res 177:69–83. doi:10.1667/RR2524.1

25. Feinendegen LE, Pollycove M, Neumann RD (2013) Hormesis by low dose radiation effects: Low-dose cancer risk modeling must recognize up-regulation of protection In: Baum RP (ed) Therapeutic nuclear medicine. Springer, Berlin, pp 789–805 doi:10.1007/174_2012_686

26. Yu H, Liu N, Wang H, Shang Q, Jiang P, Zhang Y (2013) Different responses of tumor and normal cells to low-dose radiation. Contemp Oncol (Pozn) 17:356–362. doi:10.5114/wo.2013.35289

27. Brooks AL, Dauer LT (2014) Advances in radiation biology: effect on nuclear medicine. Semin Nucl Med 44:179–186. doi:10.1053/j.semnuclmed.2014.03.004

28. Wodarz D, Sorace R, Komarova NL (2014) Dynamics of cellular responses to radiation. PLoS Comput Biol 2014 10:e1003513. doi:10.1371/journal.pcbi.1003513

29. Yang G, Li W, Jiang H, Liang X, Zhao Y, Yu D et al (2016) Low-dose radiation may be a novel approach to enhance the effectiveness of cancer therapeutics. Int J Cancer 139:2157–2168. doi:10.1002/ijc.30235

30. Rowland RE (1970) Dose and damage in long term radium cases. In Cloutier RJ, Edwards CL, Snyder WS (eds), Medical radionuclides: radiation dose and effects: Proceedings of a Symposium held at the Oak Ridge Associated Universities, Dec 8–11, 1969. Publ.: US Atomic Energy Comission, Division of Technical Information (available from Clearinghouse for Federal Scientific and Technical Information, Springfield, VA), pp 369–386

31. Nambi KS, Soman SD (1987) Environmental radiation and cancer in India. Health Phys 52:653–657. doi:10.1097/00004032-198705000-00018

32. Nambi KS, Soman SD (1990) Further observations on environmental radiation and cancer in India. Health Phys 59:339–344

33. Wei LX, Zha YR, Tao ZF, He WH, Chen DQ, Yuan YL (1990) Epidemiological investigation of radiological effects in high background radiation areas of Yangjiang, China. J Radiat Res 31:119–136. doi:10.1269/jrr.31.119

34. Mifune M, Sobue T, Arimoto H, Komoto Y, Kondo S, Tanooka H (1992) Cancer mortality survey in a spa area (Misasa, Japan) with a high radon background. Jpn J Cancer Res 83:1–5. doi:10.1111/j.1349-7006.1992.tb02342.x

35. Ye W, Sobue T, Lee VS, Tanooka H, Mifune M, Suyama A et al (1998) Mortality and cancer incidence in Misasa, Japan, a spa area with elevated radon levels. Jpn J Cancer Res 89:789–796. doi:10.1111/j.1349-7006.1998.tb00630.x

36. Nair RR, Rajan B, Akiba S, Jayalekshmi P, Nair MK, Gangadharan P et al (2009) Background radiation and cancer incidence in Kerala, India-Karanagappally cohort study. Health Phys 96:55–66. doi:10.1097/01.HP.0000327646.54923.11

37. Fornalski KW, Dobrzyński L (2012) The cancer mortality in high natural radiation areas in Poland. Dose Response 10:541–561. doi:10.2203/dose-response.11-035.Fornalski

38. Aliyu AS, Ramli AT (2015) The world’s high background natural radiation areas (HBNRAs) revisited: A broad overview of the dosimetric, epidemiological and radiobiological issues. Radiat Meas 73:51–59. doi:10.1016/j.radmeas.2015.01.007

39. Cohen BL (1989) Expected indoor 222Rn levels in counties with very high and very low lung cancer rates. Health Phys 57:897–907. doi:10.1097/00004032-198912000-00004

40. Cohen BL (1995) Test of the linear-no threshold theory of radiation carcinogenesis for inhaled radon decay products. Health Phys 68:157–174. doi:10.1097/00004032-199502000-00002

41. Cohen BL (1997) Lung cancer rate vs mean radon level in US counties of various characteristics. Health Phys 72:114–119. doi:10.1097/00004032-199701000-00016

42. Cohen BL (2008) The linear no-threshold theory of radiation carcinogenesis should be rejected. JPandS 13:70–76

43. Becker K (2003) Health effects of high radon environments in central. Europe: Another test for the LNT hypothesis? Nonlinearity Biol Toxicol Med 1:3–35. doi:10.1080/15401420390844447

44. Miller AB, Howe GR, Sherman GJ, Lindsay JP, Yaffe MJ, Dinner PJ et al (1989) Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. New Eng J Med 321:1285–1289. doi:10.1056/NEJM198911093211902

45. Kostyuchenko VA, Krestinina LYu (1994) Long-term irradiation effects in the population evacuated from the East-Urals radioactive trace area. Sci Total Environ 142:119–125. doi:10.1016/0048-9697(94)90080-9

46. Doody MM, Mandel JS, Lubin JH, Boice JD Jr (1998) Mortality among United States radiologic technologists, 1926–90. Cancer Causes Control 9:67–75. doi:10.1023/A:1008801404245

47. Berrington A, Darby SC, Weiss HA, Doll R (2001) 100 years of observation on British radiologists: mortality from cancer and other causes 1897–1997. Br J Radiol 74:507–519. doi:10.1259/bjr.74.882.740507

48. Mohan AK, Hauptmann M, Freedman DM, Ron E, Matanoski GM, Lubin JH et al (2003) Cancer and other causes of mortality among radiologic technologists in the United States. Int J Cancer 103:259–267. doi:10.1002/ijc.10811

49. Omar RZ, Barber JA, Snith PG (1999) Cancer mortality and morbidity among plutonium workers at the Sellafield plant of British nuclear fuels. Br J Cancer 79:1288–1301. doi:10.1038/sj.bjc.6690207

50. McGeoghegan D, Binks K (2000) The mortality and cancer morbidity experience of workers at the Capenhurst uranium enrichment facility 1946–95. J Radiol Prot 20:381–401. doi:10.1088/0952-4746/20/4/303

51. Boice JD Jr, Bigbee WL, Mumma MT, Blot WJ (2003) Cancer mortality in counties near two former nuclear materials processing facilities in Pennsylvania, 1950–1995. Health Phys 85:691–700. doi:10.1097/00004032-200312000-00014

52. Atkinson WD, Law DV, Bromley KJ, Inskip HM (2004) Mortality of employees of the United Kingdom Atomic Energy Authority, 1946–1997. Occup Environ Med 61:577–585. doi:10.1136/oem.2003.012443

53. Sponsler R, Cameron JR (2005) Nuclear shipyard worker study (1980–1988): a large cohort exposed to low-dose-rate gamma radiation. Int J Low Radiat 1:463–478. doi:10.1504/IJLR.2005.007915

54. Boice JD Jr, Mumma MT, Blot WJ (2006) Cancer mortality among populations residing in counties near the Hanford site, 1950–2000. Health Phys 90:431–445. doi:10.1097/01.HP.0000183762.47244.bb

55. Hwang SL, Guo HR, Hsieh WA, Hwang JS, Lee SD, Tang JL et al (2006) Cancer risks in a population with prolonged low dose-rate ɣ -radiation exposure in radiocontaminated buildings, 1983–2002. Int J Radiat Biol 82:849–858. doi:10.1080/09553000601085980

56. Boice JD Jr, Mumma MT, Blot WJ (2007) Cancer and noncancer mortality in populations living near uranium and vanadium mining and milling operations in Montrose County, Colorado, 1950–2000. Radiat Res 167:711–726. doi:10.1667/RR0839.1

57. Cardis E, Vrijheid M, Blettner M, Gilbert E, Hakama M, Hill C et al (2007) The 15-Country collaborative study of cancer risk among radiation workers in the nuclear industry: estimates of radiation-related cancer risks. Radiat Res 167:396–416. doi:10.1667/RR0553.1

58. Minister of Public Works and Government Services Canada, Canadian Nuclear Safety Commission (CNSC) (2011) Verifying Canadian nuclear energy worker radiation risk: A reanalysis of cancer mortality in Canadian nuclear energy workers (1957–1994) Summary report (2011). ISBN 978-1-100-17760-1

59. Thompson RE, Nelson DF, Popkin JH, Popkin Z (2008) Case-control study of lung cancer from residential radon exposure in Worcester county, Massachusetts. Health Phys 94:228–241. doi:10.1097/01.HP.0000288561.53790.5f

60. Thompson RE (2010) Epidemiological evidence for possible radiation hormesis from radon exposure: a case-control study conducted in Worcester, MA. Dose Response 9:59–75. doi:10.2203/dose-response.10-026.Thompson

61. UNSCEAR (2008) Report (2011): Sources and Effects of Ionizing Radiation United Nations Scientific Committee on the Effects of Atomic Radiation Vol II: Effects, Scientific Annex D, United Nations, New York, pp 45–219

62. Jaworowski Z (2010) Observations on the Chernobyl disaster and LNT. Dose Response 8:148–171. doi:10.2203/dose-response.09-029.Jaworowski

63. Ivanov VK, Tsyb AF (2013) Thyroid cancer: lessons of Chernobyl and prognosis for Fukushima. Vestn Ross Akad Med Nauk (5):38–44.

64. Jargin SV (2014) Chernobyl-related cancer and precancerous lesions: incidence increase vs late diagnostics. Dose Response 12:404–415. doi:10.1504/IJLR.2006.012017

65. Tubiana M, Diallo I, Chavaudra J, Lefkopoulos D, Bourhis J, Girinsky T et al (2011) A new method of assessing the dose-carcinogenic effect relationship in patients exposed to ionizing radiation A concise presentation of preliminary data. Health Phys 100:296–299. doi:10.1097/HP.0b013e31820a1b35

66. Lehrer S, Rosenzweig KE (2015) Lung cancer hormesis in high impact States where nuclear testing occurred. Clin Lung Cancer 16:152–155. doi:10.1016/j.cllc.2014.09.010

67. Bhattacharjee D (1996) Role of radioadaptation on radiation-induced thymic lymphoma in mice. Mutat Res 358:231–235. doi:10.1016/S0027-5107(96)00125-X

68. Hashimoto S (1997) Effects of low-dose total body irradiation (TBI) on tumor-bearing rats. Nihon Igaku Hoshasen Gakkai Zasshi 57:418–424

69. Hashimoto S, Shirato H, Hosokawa M, Nishioka T, Kuramitsu Y, Matushita K et al (1999) The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumour-bearing rats. Radiat Res 151:717–724. doi:10.1016/S0360-3016(98)80333-7

70. Mitchel RE, Jackson JS, McCann RA, Boreham DR (1999) The adaptive response modifies latency for radiation-induced myeloid leukemia in CBA/H mice. Radiat Res 152:273–279. doi:10.2307/3580327

71. Mitchel RE, Jackson JS, Morrison DP, Carlisle SM (2003) Low doses of radiation increase the latency of spontaneous lymphomas and spinal osteosarcomas in cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res 159:320–327. doi:10.1667/0033-7587(2003)159[0320:LDORIT]2.0.CO;2

72. Redpath JL, Lu Q, Lao X, Molloi S, Elmore E (2003) Low doses of diagnostic energy X-rays protect against neoplastic transformation in vitro. Int J Radiat Biol 79:235–240. doi:10.1080/0955300031000096306

73. Yu HS, Song AQ, Lu YD, Qiu WS, Shen FZ (2004) Effects of low-dose radiation on tumour growth, erythrocyte immune function and SOD activity in tumour-bearing mice. Chin Med J (Engl) 117:1036–1039

74. Yu HS, Liu ZM, Yu XY, Song AQ, Liu N, Wang H (2013) Low-dose radiation induces antitumour effects and erythrocyte system hormesis. Asian Pac J Cancer Prev 14:4121–4126. doi:10.7314/APJCP.2013.14.7.4121

75. Ina Y, Tanooka H, Yamada T, Sakai K (2005) Suppression of thymic lymphoma induction by life-long low-dose-rate irradiation accompanied by immune activation in C57BL/6 mice. Radiat Res 163:153–158. doi:10.1667/RR3289

76. Ishii K, Hosoi Y, Yamada S, Ono T, Sakamoto K (1996) Decreased incidence of thymic lymphoma in AKR mice as a result of chronic, fractionated low-dose total-body X irradiation. Radiat Res 146:582–585. doi:10.2307/3579560

77. Jin SZ, Pan XN, Wu N, Jin GH, Liu SZ (2007) Whole-body low dose irradiation promotes the efficacy of conventional radiotherapy for cancer and possible mechanisms. Dose Response 5:349–358. doi:10.2203/dose-response.07-020.Jin

78. Wu N, Jin SZ, Pan XN, Liu SZ (2008) Increase in efficacy of cancer radiotherapy by combination with whole-body low dose irradiation. Int J Radiat Biol 84:201–210. doi:10.1080/09553000801902133

79. Ogura K, Magae J, Kawakami Y, Koana T (2009) Reduction in mutation frequency by very low-dose gamma irradiation of Drosophila melanogaster germ cells. Radiat Res 171:1–8. doi:10.1667/RR1288.1

80. Fisher DR, Weller RE (2010) Carcinogenesis from inhaled (239)PuO(2) in beagles: Evidence for radiation homeostasis at low doses? Health Phys 99:357–362. doi:10.1097/HP.0b013e3181bfa16b

81. Cheda A, Wrembel-Wargocka J, Lisiak E, Marciniak M, Nowosielska EM, Janiak MK (2004) Inhibition of the development of pulmonary tumour nodules and stimulation of the activity of NK cells and macrophages in mice by single low doses of low-LET radiation. Int J Low Radiat 1:171–179. doi:10.1504/IJLR.2004.003868

82. Cheda A, Wrembel-Wargocka J, Lisiak E, Nowosielska EM, Marciniak M, Janiak MK (2004) Single low doses of X rays inhibit the development of experimental tumour metastases and trigger the activities of NK cells in mice. Radiat Res 161:335–340. doi:10.1667/RR3123

83. Cheda A, Wrembel-Wargocka J, Nowosielska EM, Janiak MK (2006) Immune mechanism of the retarded growth of tumor nodules in mice exposed to single low-level irradiations with X-rays. Centr. Eur J Immunol 31:44–50

84. Janiak MK, Wrembel-Wargocka J, Cheda A, Nowosielska EM, Lisiak E, Bilski M (2006) Modulation of anti-tumour functions of NK cells and macrophages after single low-level exposures of mice to X-rays. Int J Low Radiat 3:178–191. doi:10.1504/IJLR.2006.012017

85. Nowosielska EM, Wrembel-Wargocka J, Cheda A, Lisiak E, Janiak MK (2005) Low-level exposures to ionising radiation modulate the anti-tumour activity of murine NK cells. Nukleonika 50(suppl 2):21–24

86. Nowosielska EM, Wrembel-Wargocka J, Cheda A, Lisiak E, Janiak MK (2006) Enhanced cytotoxic activity of macrophages and suppressed tumour metastases in mice irradiated with low doses of X-rays. J Radiat Res 47:229–236. doi:10.1269/jrr.0572

87. Nowosielska EM, Cheda A, Wrembel-Wargocka J, Janiak MK (2008) Modulation of the growth of pulmonary tumour colonies in mice after single or fractionated low-level irradiations with X-rays. Nukleonika 53(suppl 1):s9–s15

88. Nowosielska EM, Cheda A, Wrembel-Wargocka J, Janiak MK (2009) Immunological mechanism of the low-dose radiation-induced suppression of cancer metastases in a mouse model. Dose Response 8:209–226. doi:10.2203/dose-response.09-016.Nowosielska

89. Nowosielska EM, Cheda A, Wrembel-Wargocka J, Janiak MK (2011) Anti-neoplastic and immuno-stimulatory effects of low-dose X-ray fractions in mice. Int J Radiat Biol 87:202–212. doi:10.3109/09553002.2010.519422

90. Nowosielska EM, Cheda A, Wrembel-Wargocka J, Janiak MK (2012) Effect of low doses of low-let radiation on the innate anti-tumor reactions in radioresistant and radiosensitive mice. Dose Response 10:500–515. doi:10.2203/dose-response.12-018.Nowosielska

91. Bruce VR, Belinsky SA, Gott K, Liu Y, March T, Scott B, Wilder J (2012) Low-dose gamma-radiation inhibits benzo[a]pyrene-induced lung adenoma development in A/J mice. Dose Response 10:516–526. doi:10.2203/dose-response.12-040.Bruce

92. Bauer G (2007) Low dose radiation and intercellular induction of apoptosis: potential implications for the control of oncogenesis. Int J Radiat Biol 83:873–888. doi:10.1080/09553000701727523

93. Scott BR (2008) Low-dose-radiation stimulated natural chemical and biological protection against lung cancer. Dose Response 6:299–318. doi:10.2203/dose-response.07-025.Scott

94. Scott BR (2014) Radiation-hormesis phenotypes, the related mechanisms and implications for disease prevention and therapy. J Cell Commun Signal 8:341–352. doi:10.1007/s12079-014-0250-x

95. Shao M, Lu X, Cong W, Xing X, Tan Y, Li Y et al (2014) Multiple low-dose radiation prevents type 2 diabetes-induced renal damage through attenuation of dyslipidemia and insulin resistance and subsequent renal inflammation and oxidative stress. PLoS One 9(3):e92574. doi:10.1371/journal.pone.0092574

96. Safwat A (2000) The immunobiology of low-dose total-body irradiation: more questions than answers. Radiat Res 153:599–604. doi:10.1667/0033-7587(2000)153[0599:TIOLDT]2.0.CO;2

97. Liu SZ (2003) On radiation hormesis expressed in the immune system. Crit Rev Toxicol 33:431–441. doi:10.1080/713611045

98. Liu XD, Ma SM, Liu SZ (2003) Effects of 0.075 Gy X-ray irradiation on the expression of IL-10 and IL-12 in mice. Phys Med Biol 48:2041–2049. doi:10.1088/0031-9155/48/13/315

99. Liu SZ (2006) Cancer control related to stimulation of immunity by low-dose radiation. Dose Response 5:39–47. doi:10.2203/dose-response.06-108.Liu

100. Sakamoto K (2004) Radiobiological basis for cancer therapy by total or half-body irradiation. Nonlinearity Biol Toxicol Med 2:293–316. doi:10.1080/15401420490900254

101. Pollycove M (2006) Radiobiological basis of low-dose irradiation in prevention and therapy of cancer. Dose Response 5:26–38. doi:10.2203/dose-response.06-112.Pollycove

102. Chaffey JT, Rosenthal DS, Moloney WC, Hellman S (1976) Total body irradiation as treatment for lymphosarcoma. Int J Radiat Oncol Biol Phys 1:399–405. doi:10.1016/0360-3016(76)90004-3

103. Choi NC, Timothy AR, Kaufman SD, Carey RW, Aisenberg AC (1979) Low dose fractionated whole body irradiation in the treatment of advanced non-Hodgkin’s lymphoma. Cancer 43:1636–1642. doi:10.1002/1097-0142(197905)

104. Cuttler JM, Pollycove M (2003) Can cancer be treated with low doses of radiation? JPandS 8:108–111.

105. Safwat A, Bayoumy Y, El-Sharkawy N, Shaaban K, Mansour O, Kamel A (2003) The potential palliative role and possible immune modulatory effects of low-dose total body irradiation in relapsed or chemo-resistant non-Hodgkin’s lymphoma. Radiother Oncol 69:33–36. doi:10.1016/S0167-8140(03)00247-0

106. Farooque A, Mathur R, Verma A, Kaul V, Bhatt AN, Adhikari JS et al (2011) Low-dose radiation therapy of cancer: role of immune enhancement. Expert Rev Anticancer Ther 11:791–802. doi:10.1586/era.10.217

107. Gatti RA, Good RA (1971) Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28:89–98. doi:10.1002/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q

108. Stutman O (1974) Tumour development after 3-methylcholanthrene in immunologically deficient athymic mice. Science 183:534–536. doi:10.1126/science.183.4124.534

109. Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumour variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumour immune escape. Cancer Immunol Immunother 53:904–910. doi:10.1007/s00262-004-0517-9

110. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F (2007) MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 256:139–189. doi:10.1016/S0074-7696(07)56005-5

111. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400–404. doi:10.1038/nature10755

112. Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W et al (2014) Recognition of tumours by the innate immune system and natural killer cells. Adv Immunol 122:91–128. doi:10.1016/B978-0-12-800267-4.00003-1

113. Seong SY, Matzinger P (2004) Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4:469–478. doi:10.1038/nri1372

114. Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J et al (2014) HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res 74:5723–5733. doi:10.1158/0008-5472.CAN-13-2347

115. Jia L, Clear A, Liu FT, Matthews J, Uddin N, McCarthy A et al (2014) Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood 123:1709–1719. doi:10.1182/blood-2013-10-529610

116. Pardoll D (2003) Does the immune system see tumours as foreign or self? Annu Rev Immunol 21:807–839. doi:10.1146/annurev.immunol.21.120601.141135

117. Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23:263–272. doi:10.1385/IR:23:2-3:263

118. Kim R, Emi M, Tanabe K, Arihiro K (2006) Tumour-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66:5527–5536. doi:10.1158/0008-5472.CAN-05-4128

119. Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 37:764–782. doi:10.1016/j.clinthera.2015.02.018

120. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982. doi:10.1200/JCO.2014.59.4358

121. Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309. doi:10.1158/1078-0432.CCR-13-0143

122. Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G (2014) Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an “innocent bystander”. Toxins 6: 914–933. doi:10.3390/toxins6030914

123. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242. doi:10.1111/j.1600-065X.2010.00923.x

124. Roychoudhuri R, Eil RL, Restifo NP (2015) The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol 33:101–111. doi:10.1016/j.coi.2015.02.003

125. Takeuchi Y, Nishikawa H (2016) Roles of regulatory T cells in cancer immunity. Int Immunol 28:401–409. doi:10.1093/intimm/dxw025

126. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523–532. doi:10.1038/nri2343

127. Pyzer AR, Cole L, Rosenblatt J, Avigan DE (2016) Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int J Cancer 139:1915–1926. doi:10.1002/ijc.30232

128. Achyut BR, Arbab AS (2016) Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther 9:1047–1055. doi:10.2147/OTT.S102907

129. Meirow Y, Kanterman J, Baniyash M (2015) Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate. Front Immunol 6:523. doi:10.3389/fimmu.2015.00523

130. Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P et al (2016) Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. doi:10.1007/s00281-016-0597-6

131. Kim J, Bae JS (2016) Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm 2016:6058147. doi:10.1155/2016/6058147

132. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–555. doi:10.1016/S1471-4906(02)02302-5

133. Sainz B Jr, Carron E, Vallespinós M, Machado HL (2016) Cancer stem cells and macrophages: Implications in tumor biology and therapeutic strategies. Mediators Inflamm 2016:9012369. doi:10.1155/2016/9012369

134. Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277–348. doi:10.1016/S0065-230X(08)00408-9

135. Macho-Fernandez E, Brigl M (2015) The extended family of CD1d-restricted NKT cells: Sifting through a mixed bag of TCRs, antigens, and functions. Front Immunol 6:362. doi:10.3389/fimmu.2015.00362

136. Shissler SC, Bollino DR, Tiper IV, Bates JP, Derakhshandeh R, Webb TJ (2016) Immunotherapeutic strategies targeting natural killer T cell responses in cancer. Immunogenetics 68:623–638. doi:10.1007/s00251-016-0928-8

137. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR et al (2009) A human colonic commensal promotes colon tumourigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016–1022. doi:10.1089/cbr.2014.1702

138. Maniati E, Soper R, Hagemann T (2010) Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29:5653–5662. doi:10.1038/onc.2010.367

139. Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10:248–256. doi:10.1038/nri2742

140. Zhang Y, Morgan R, Podack ER, Rosenblatt J (2013) B cell regulation of anti-tumor immune response. Immunol Res 57:115–124. doi:10.1007/s12026-013-8472-1

141. Candando KM, Lykken JM, Tedder TF (2014) B10 cell regulation of health and disease. Immunol Rev 259:259–272. doi:10.1111/imr.12176

142. Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, Rosenblatt JD (2013) B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother 62:87–99. doi:10.1007/s00262-012-1313-6

143. Zhang Y, Morgan R, Chen C, Cai Y, Clark E, Khan WN et al (2016) Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses. Int Immunol 28:423–423. doi:10.1093/intimm/dxw007

144. Sionov RV, Fridlender ZG, Granot Z (2015) The multifaceted roles neutrophils play in the tumour microenvironment. Cancer Microenviron 8:125–158. doi:10.1007/s12307-014-0147-5

145. Coffelt SB, Wellenstein MD, De Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431–446. doi:10.1038/nrc.2016.52

146. Piccard H, Muschel RJ, Opdenakker G (2012) On the dual roles and polarized phenotypes of neutrophils in tumour development and progression. Crit Rev Oncol Hematol 82:296–309. doi:10.1016/j.critrevonc.2011.06.004

147. Dumitru CA, Lang S, Brandau S (2013) Modulation of neutrophil granulocytes in the tumour microenvironment: mechanisms and consequences for tumour progression. Semin Cancer Biol 23:141–148. doi:10.1016/j.semcancer.2013.02.005

148. Hurwitz AA, Watkins SK (2012) Immune suppression in the tumour microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother 61:289–293. doi:10.1007/s00262-011-1181-5

149. Huang XM, Liu XS, Lin XK, Yu H, Sun JY, Liu XK et al (2014) Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer. Cancer Sci 105:150–158. doi:10.1111/cas.12327

150. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumour-induced immune suppression. Semin Cancer Biol 22:275–281. doi:10.1016/j.semcancer.2012.01.011

151. Ramos RN, de Moraes CJ, Zelante B, Barbuto JA (2013) What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer? Clin Dev Immunol 2013:806025. doi:10.1155/2013/806025

152. Dalton DK, Noelle RJ (2012) The roles of mast cells in anticancer immunity. Cancer Immunol Immunother 61:1511–1520. doi:10.1007/s00262-012-1246-0

153. Yi T, Song SU (2012) Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 35:213–221. doi:10.1007/s12272-012-0202-z

154. Barcellos-de-Souza P, Gori V, Bambi F, Chiarugi P (2013) Tumour microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biphys Acta 1836:321–335. doi:10.1016/j.bbcan.2013.10.004

155. Puré E, Lo A (2016) Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res 4:269–278. doi:10.1158/2326-6066.CIR-16-0011

156. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi:10.1038/nature07205

157. Candido J, Hagemann T (2013) Cancer-related inflammation. J Clin Immunol 33(Suppl 1):S79–S84. doi:10.1007/s10875-012-9847-0

158. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani (2009) A Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081. doi:10.1093/carcin/bgp127

159. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. doi:10.1016/j.cell.2010.01.025

160. Pal S, Bhattacharjee A, Ali A, Mandal NC, Mandal SC, Pal M (2014) Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) 11:23. doi:10.1186/1476-9255-11-23

161. Khan S, Jain M, Mathur V, Feroz SM (2016) Chronic inflammation and cancer: paradigm on tumor progression, metastasis and therapeutic intervention. Gulf J Oncolog 1:86–93

162. Romano M, DE Francesco F, Zarantonello L, Ruffolo C, Ferraro GA, Zanus G et al (2016) From inflammation to cancer in inflammatory bowel disease: molecular perspectives. Anticancer Res 36:1447–1460

163. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S (2009) Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 85:996–1004. doi:10.1189/jlb.0708446

164. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–4506. doi:10.4049/jimmunol.0802740

165. Kent A, Blander JM (2014) Nod-like receptors: key molecular switches in the conundrum of cancer. Front Immunol 5:185–189. doi:10.3389/fimmu.2014.00185

166. Saxena M, Yeretssian G (2014) NOD-like receptors: master regulators of inflammation and cancer. Front Immunol 5:327–342. doi:10.3389/fimmu.2014.00327

167. Feinendegen LE, Pollycove M, Neumann RD (2009) Low-dose cancer risk modeling must recognize up-regulation of protection. Dose Response 8:227–252. doi:10.2203/dose-response.09-035.Feinendegen

168. Mitchel RE, Jackson JS, Carlisle SM (2004) Upper dose threshold for radiation-induced adaptive response against cancer in high-dose-exposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res 162:20–30. doi:10.1667/RR3190

169. Taylor LS (1980) Some nonscientific influences on radiation protection standards and practice. The 1980 Sievert Lecture. Health Phys 39:851–874

170. Zhang C, Jin S, Guo W, Li C, Li X, Rane MJ et al (2011) Attenuation of diabetes-induced cardiac inflammation and pathological remodeling by low-dose radiation. Radiat Res 175:307–321. doi:10.1667/RR1950.1

171. Calabrese EJ (2015) An abuse of risk assessment: how regulatory agencies improperly adopted LNT for cancer risk assessment. Arch Toxicol 89:647–648. doi:10.1007/s00204-015-1454-4

172. Anderson RE, Tokuda S, Williams WL, Warner NL (1982) Radiation-induced augmentation of the response of A/J mice to SaI tumor cells. Am J Pathol 108:24–37

173. Kharazi AI, James SJ, Taylor JM, Lubinski JM, Nakamura LT, Makinodan T (1994) Combined chronic low dose radiation-caloric restriction: a model for regression of spontaneous mammary tumor. Int J Radiat Oncol Biol Phys 28:641–647. doi:10.1016/0360-3016(94)90189-9

174. Lacoste-Collin L, Jozan S, Cances-Lauwers V, Pipy B, Gasset G, Caratero C, Courtade-Saïdi M (2007) Effect of continuous irradiation with a very low dose of gamma rays on life span and the immune system in SJL mice prone to B-cell lymphoma. Radiat Res 168:725–732. doi:10.1667/RR1007.1

175. Wang B, Li B, Dai Z, Ren S, Bai M, Wang Z et al (2014) Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4 + CD25 + Treg cells. Int J Biochem Cell Biol 55:98–108. doi:10.1016/j.biocel.2014.08.014

176. Cheda A, Wrembel-Wargocka J, Nowosielska EM, Janiak MK (2005) Stimulatory effects of a single low-level irradiations with X-rays on functions of murine peritoneal macrophages. Nukleonika 50(suppl 2):13–16.

177. Cheda A, Nowosielska EM, Wrembel-Wargocka J, Janiak MK (2008) Production of cytokines by peritoneal macrophages and splenocytes after exposures of mice to low doses of X-rays. Radiat Environ Biophys 47:275–283. doi:10.1007/s00411-007-0147-7

178. Cheda A, Nowosielska EM, Wrembel-Wargocka J, Janiak MK (2009) Single or fractionated irradiations of mice with low doses of X-rays stimulate innate immune mechanisms. Int J Low Radiat 6:325–342. doi:10.1504/IJLR.2009.029312

179. Nowosielska EM, Wrembel-Wargocka J, Cheda A, Janiak MK (2006) A single low-dose irradiation with X-rays stimulates NK cells and macrophages to release factors related to the cytotoxic functions of these cells. Centr Eur J Immunol 31:51–56

180. Pollycove M, Feinendegen LE (2011) Low-dose radiotherapy of disease. Health Phys 100:322–324. doi:10.1097/HP.0b013e318208423b

181. Holder DL (1965) Total body irradiation in multiple myeloma. Radiology 84:82–86

182. Kazem I (1975) Total body irradiation in the management of malignant lymphoma. Radiol Clin 44:457–463.

183. Qasim MM (1975) Total body irradiation in non-Hodgkin lymphoma. Strahlentherapie 149:364–367.

184. Richaud PM, Soubeyran P, Eghbali H, Chacon B, Marit G, Broustet A, Hoerni B (1998) Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin’s lymphoma: results of a pilot study. Int J Radiat Oncol Biol Phys 40:387–390. doi:10.1016/S0360-3016(97)00722-0

185. Jaworowski Z (1999) Radiation risk and ethics. Phys Today 52:24–29

186. Tanooka H (2001) Threshold dose-response in radiation carcinogenesis: an approach from chronic beta-irradiation experiments and a review of non-tumour doses. Int J Radiat Biol 77:541–551. doi:10.1080/09553000110034612

187. Scott BR (2008) It’s time for a new low-dose-radiation risk assessment paradigm—one that acknowledges hormesis. Dose Response 6:333–351. doi:10.2203/dose-response.07-005.Scott

188. Tubiana M, Feinendegen LE, Yang C, Kaminski JM (2009) The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology 251:13–22. doi:10.1148/radiol.2511080671

189. Cuttler JM (2010) Commentary on using LNT for radiation protection and risk assessment. Dose Response 8:378–383. doi:10.2203/dose-response.10-003.Cuttler

190. Ulsh BA (2012) The new radiobiology: returning to our roots. Dose Response 10:593–609. doi:10.2203/dose-response.12-021.Ulsh

191. Calabrese EJ (2013) Origin of the linearity no threshold (LNT) dose-response concept. Arch Toxicol 87:1621–1633. doi:10.1007/s00204-013-1104-7

192. Socol Y, Dobrzyński L, Doss M, Feinendegen LE, Janiak MK, Miller ML et al (2013) Commentary: ethical issues of current health-protection policies on low-dose ionizing radiation. Dose Response 12:342–348. doi:10.2203/dose-response.13-044.Socol

193. Kesavan PC (2014) Linear, no threshold response at low doses of ionizing radiation: ideology, prejudice and science. Curr Sci India 107:46–53.

194. Mitchel REJ (2007) Cancer and low dose responses in vivo: implications for radiation protection. Dose Response 5:284–291. doi:10.2203/dose-response.07-014.Mitchel

195. Marcus CS (2015) Time to reject the linear-no threshold hypothesis and accept thresholds and hormesis: a petition to the U.S. Nuclear Regulatory Commission. Clin Nucl Med 40:617–619. doi:10.1097/RLU.0000000000000835

196. Sonn CH, Choi JR, Kim TJ, Yu YB, Kim K, Shin SC et al (2012) Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. J Radiat Res 53:823–829. doi:10.1093/jrr/rrs037

197. Yang G, Kong Q, Wang G, Jin H, Zhou L, Yu D et al (2014) Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm 29:428–434. doi:10.1089/cbr.2014.1702

198. Liu SZ, Jin SZ, Liu XD, Sun YM (2001) Role of CD28/B7 costimulation and IL-12/IL-10 interaction in the radiation-induced immune changes. BMC Immunol 2:8. doi:10.1186/1471-2172-2-8

199. Sambani C, Thomou H, Kitsiou P (1996) Stimulatory effect of low dose X-irradiation on the expression of the human T lymphocyte CD2 surface antigen. Int J Radiat Biol 70:711–717. doi:10.1080/095530096144608

200. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:1186–1190. doi:10.1038/nature03884

201. Schaue D, Ratikan JA, Iwamoto KS, McBride WH (2012) Maximizing tumour immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306–1310. doi:10.1016/j.ijrobp.2011.09.049

202. Hellweg CE (2015) The nuclear factor κB pathway: a link to the immune system in the radiation response. Cancer Lett 368:275–289. doi:10.1016/j.canlet.2015.02.019

203. Chen Y, Chen X, Li Y, Zhang H, Xie Y, Zhang X et al (2011) Early effects of low dose C ion or X-ray irradiation on peripheral blood lymphocytes of patients with alimentary tract cancer. Dose Response 9:356–368. doi:10.2203/dose-response.10-015.Chen

204. Chen Y, Wang C, He M, Zhang H, Chen X (2014) Effect of low dose heavy ion irradiation on subset percentage and cytokines expression of peripheral blood lymphocytes in patients with pancreatic cancer. Zhonghua Zhong Liu Za Zhi 36:435–439

205. Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ (2015) A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy. J Am Chem Soc 137:14854–14857. doi:10.1021/jacs.5b10182

206. Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong J et al (2015) Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology 5:e1063772. doi:10.1080/2162402X.2015.1063772

207. Achkova D, Maher J (2016) Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. Biochem Soc Trans 44:333–341. doi:10.1042/BST20150245

208. Drakes ML, Stiff PJ (2014) Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. Immunotargets Ther 3:151–165. doi:10.2147/ITT.S37790

209. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N et al (2013) Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24:589–602. doi:10.1016/j.ccr.2013.09.014

210. De Palma M, Lewis CE (2013) Macrophage regulation of tumour responses to anticancer therapies. Cancer Cell 23:277–286. doi:10.1016/j.ccr.2013.02.013

211. Tazzyman S, Niaz H, Murdoch C (2013) Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin Cancer Biol 23:149–158. doi:10.1016/j.semcancer.2013.02.003

212. Duan MC, Zhong XN, Liu GN, Wei JR (2014) The Treg/Th17 paradigm in lung cancer. J Immunol Res 2014:730380. doi:10.1155/2014/730380

213. Zhou J, He LL, Ding XF, Yuan QQ, Zhang JX, Liu SC, Chen G (2016) Combinatorial antitumor effect of rapamycin and β-elemene in follicular thyroid cancer cells. Biomed Res Int 2016:6723807. doi:10.1155/2016/6723807

214. Matsuo K, Itoh T, Koyama A, Imamura R, Kawai S, Nishiwaki K et al (2016) CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma. Cancer Lett 378:16–22. doi:10.1016/j.canlet.2016.04.039

215. Shan YX, Jin SZ, Liu XD, Liu Y, Liu SZ (2007) Ionizing radiation stimulates secretion of pro-inflammatory cytokines: dose-response relationship, mechanisms and implications. Radiat Environ Biophys 46:21–29. doi:10.1007/s00411-006-0076-x

216. Roses RE, Datta J, Czerniecki BJ (2014) Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat Res 182:211–218. doi:10.1667/RR13495.1

217. Schölch S, Rauber C, Weitz J, Koch M, Huber PE (2015) TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities. Oncoimmunology 4:e1042201. doi:10.1080/2162402X.2015.1042201

218. Zhang C, Tan Y, Guo W, Li C, Ji S, Li X, Cai L (2009) Attenuation of diabetes-induced renal dysfunction by multiple exposures to low-dose radiation is associated with the suppression of systemic and renal inflammation. Am J Physiol Endocrinol Metab 297:E1366–E1377. doi:10.1152/ajpendo.00478

219. Xing X, Zhang C, Shao M, Tong Q, Zhang G, Li C et al (2012) Low-dose radiation activates Akt and Nrf2 in the kidney of diabetic mice: a potential mechanism to prevent diabetic nephropathy. Oxid Med Cell Longev 2012:291087. doi:10.1155/2012/291087

220. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E et al (2017) Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 23:124–136. doi:10.1158/1078-0432.CCR-15-1535

221. Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A et al (2016) Combination of radiotherapy and vaccination overcome checkpoint blockade resistance. Oncotarget 7:43039–43051. doi:10.18632/oncotarget.9915